1256386-07-8

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 34404-30-3 N-(tert-butoxycarbonyl)-D-glutamic acid 1-benzyl ester 

Downstream Products

• 1310382-07-0 (S)-benzyl 2-({(R)-5-(benzyloxy)-4-[bis(tert-butoxycarbonyl)amino]-5-oxopentyl}amino)-6-benzyloxycarbonylaminohexanoate 
• 1310382-09-2 (6S,9R,14S)-benzyl 9-benzyloxycarbonyl-14-(4-benzyloxycarbonylaminobutyl)-2,2,6-trimethyl-4,7-dioxo-3-oxa-5,8,13-triazapentadecan-15-oate 
• 1256386-08-9 (R)-benzyl 2-[bis(tert-butoxycarbonyl)amino]-5-[methoxy(methyl)amino]-5-oxopentanoate 

Relevant academic research and scientific papers

Design and synthesis of new peptidomimetics as potential inhibitors of MurE

With the continuing emergence and spread of multidrug-resistant bacteria, there is an urgent need for the development of new antimicrobial agents. One possible source of new antibacterial targets is the biosynthesis of the bacterial cellwall peptidoglycan

BICYCLIC MELANOCORIN-SPECIFIC COMPOUNDS

Melanocortin receptor-specific bicyclic compounds having the structure (I) and stereoisomer and pharmaceutically acceptable salts thereof, where R1,R2,R3 X and z are as described in the specification, which are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.